Webinar – Parp-Inhibitors and Prostate Cancer…Gotta Have a Mutation???

Virtual

Parp-Inhibitors have long been on AnCan's radar since our dear departed Boardie, Dr. Bill Burhans, found himself with olaparib in his lab in 2015 and convinced his tumor board to prescribe it along with abiraterone for his BRCA2 mutation.

Question is ...

What's a PARP-Inhibitor, and what does it do?

Who benefits from a PARP?

Do PARP-I's work for everybody?

How can a PARP-I be used for prostate cancer?